Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.
... MoreBiogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM EDTBMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.
The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More
Biogen (BIIB) PT Raised to $310 at Jefferies
October 22, 2019 1:45 PM EDTJefferies analyst Michael Yee raised the price target on Biogen (NASDAQ: BIIB) to $310.00 (from $255.00) while maintaining a Hold rating.
stock pricing in renewed hopes againasks if M&A could be next... MoreBiogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
October 22, 2019 7:32 AM EDTRBC Capital analyst Brian Abrahams weighed in on news Biogen (NASDAQ: BIIB) will pursue regulatory approval of aducanumab in Alzheimer's.
"We expect more clarity on BIIB's earnings call this morning but believe that given the multi-$B potential opportunity, we could see shares initially... More
Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease
October 22, 2019 6:41 AM EDTBiogen (NASDAQ: BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimers Disease
... More